Outcomes of COVID-19 Infection in Multiple Sclerosis and Related Conditions: One-Year Pandemic Experience of the Multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)

Autor: Yinan Zhang, Tracy DeAngelis, Roland Hentz, Rebecca Straus Farber, Tyler Smith, Richard Blanck, Tung Ming Leung, Lana Zhovtis-Ryerson, Asaff Harel, Sylvia Klineova, K. Fong
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Multiple Sclerosis and Related Disorders
ISSN: 2211-0356
2211-0348
Popis: Objective To determine outcomes of COVID-19 in patients with Multiple Sclerosis (MS) and related conditions, and to determine predictors of these outcomes. Methods This was a multicenter, observational cohort study of patients with MS or related CNS autoimmune disorders who developed confirmed or highly suspected COVID-19 infection from 2/1/2020 to 12/31/2020. Main Outcome and Measure The primary outcome measure was hospitalization status due to COVID-19. Severity of infection was measured using a 4-point ordinal scale: 1. home care; 2. hospitalization without mechanical ventilation; 3. hospitalization and mechanical ventilation, and 4. death. Results Of 474 patients in the study, 63.3% had confirmed COVID-19 infection and 93.9% were diagnosed with an MS phenotype. Mean age was 45±13 (mean±SD) years, 72% were female, and 86% were treated with a DMT at the time of infection. 58 patients (12.2%) were hospitalized. 24 patients (5.1%) were critically ill (requiring ICU care or outcome of death), of which 15 patients (3.2%) died. Higher neurological disability and older age independently predicted hospitalization. 85% (102/120) of patients with known antibody results not treated with anti-CD20 therapies were seropositive while only 39.5% (17/43) of patients treated with anti-CD20 demonstrated seropositivity (p
Databáze: OpenAIRE
Externí odkaz: